I. O. Dementyev
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
I. O. Dementyev has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- A. V. Troyanov
А. Tsyb Medical Radiological Research Centre — branch of the National Medical Research Radiological Centre
6 shared publications - Vladimir Chaykov
A.F. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Center, Ministry of Health of Russia
6 shared publications - E. O. Shchukina
A.F. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Center, Ministry of Health of Russia
5 shared publications - Oleg B. Karyakin
A.F. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Center, Ministry of Health of Russia
5 shared publications - Andrei Dmitrievich Kaprin
National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, Koroleva St. 4, 249036 Obninsk, Russia
3 shared publications - Ivan N. Zaborskiy
A.Tsyb Medical Radiological Research Centre – Branch of the National Medical Research Radiological Centre Obninsk, Russian Federation
3 shared publications
Latest Publications
- Open Access
- 15 August 2024
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 20 (2) , 140-147
Brachytherapy for organ-preserving treatment of bladder cancer
Bladder cancer is the 9th most common malignant tumor worldwide. Muscle-invasive bladder cancer is an aggressive malignant neoplasm with a tendency for early metastases. The main approach for muscle-invasive bladder cancer treatment is radical cystectomy with lymph node dissection and polychemotherapy. In recent decades, organ-preserving conservative therapy has been actively investigated. Currently, the most studied approach to organ-preserving treatment of muscle-invasive bladder cancer is the trimodality therapy which includes transurethral resection of the bladder wall with the tumor, chemotherapy, and external beam radiotherapy. The article presents an approach which additionally includes intratumoral radiation therapy. In our study, we have investigated the current state of brachytherapy in bladder cancer treatment and its development.
- 15 August 2024
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 20 (2) , 140-147
Open AccessBrachytherapy for organ-preserving treatment of bladder cancer
Bladder cancer is the 9th most common malignant tumor worldwide. Muscle-invasive bladder cancer is an aggressive malignant neoplasm with a tendency for early metastases. The main approach for muscle-invasive bladder cancer treatment is radical cystectomy with lymph node dissection and polychemotherapy. In recent decades, organ-preserving conservative therapy has been actively investigated. Currently, the most studied approach to organ-preserving treatment of muscle-invasive bladder cancer is the trimodality therapy which includes transurethral resection of the bladder wall with the tumor, chemotherapy, and external beam radiotherapy. The article presents an approach which additionally includes intratumoral radiation therapy. In our study, we have investigated the current state of brachytherapy in bladder cancer treatment and its development.
- Open Access
- 18 May 2023
- Published by QUASAR, LLC in Research and Practical Medicine Journal
- Vol. 10 (2) , 31-39
Combined treatment of high and very high risk prostate cancer: results of neoadjuvant treatment
Purpose of the study. Assessment of safety and short‑term effectiveness of high and very high‑risk prostate cancer neoadjuvant chemo‑ hormonal treatment without distant metastases.Patients and methods. Combined hormone chemo‑ radiation treatment of 33 patients with prostate cancer of high and very high risk of progression without distant metastases was performed. Metastases to regional lymph nodes were found in 9 patients according to the examination data (MRI, MSCT), no metastases were detected in 24 patients. All patients underwent combined chemohormonal therapy in the amount of 4 courses of docetaxel intravenously at a dose of 75 mg/m2 every 3 weeks as the first stage of treatment. in combination with androgen deprivation therapy with agonists or antagonists of GnRH before performing radical radiation therapy (combined or remote). All patients underwent neoadjuvant hormone therapy: 16 patients – with the use of GnRH antagonists (Degarelix), 17 – with the use of GnRH agonists (Gozerelin/Leuprorelin/Triptorelin). The toxicity of the presented treatment regimen and its immediate effectiveness – the effect on the level of prostate‑s pecific antigen (PSA), prostate volume, and the quality of urination – were evaluated.Results. Treatment regimen was highly effective concerning PSA decrease (from initial median level 79,67 ng/ml to 1,45 ng/ml after neoadjuvant treatment), all subjects responded well, no non‑responders observed. Median prostate volume decreased from 44 cm3 to 25 cm3 after treatment, which guaranteed availability and safety of further radical radiation treatment. Urinary function was restored in all subject with initial urinary retention.Conclusion. Neoadjuvant chemo‑h ormonal treatment was highly effective in PSA level, prostate volume decrease and functional results improvement which secured further radical radiation treatment in one of its types. Toxicity was acceptable, adverse events did not exceed grade II in most cases and did not lead to treatment discontinuation in any cases, while quality of life remained high enough.
- 18 May 2023
- Published by QUASAR, LLC in Research and Practical Medicine Journal
- Vol. 10 (2) , 31-39
Open AccessCombined treatment of high and very high risk prostate cancer: results of neoadjuvant treatment
Purpose of the study. Assessment of safety and short‑term effectiveness of high and very high‑risk prostate cancer neoadjuvant chemo‑ hormonal treatment without distant metastases.Patients and methods. Combined hormone chemo‑ radiation treatment of 33 patients with prostate cancer of high and very high risk of progression without distant metastases was performed. Metastases to regional lymph nodes were found in 9 patients according to the examination data (MRI, MSCT), no metastases were detected in 24 patients. All patients underwent combined chemohormonal therapy in the amount of 4 courses of docetaxel intravenously at a dose of 75 mg/m2 every 3 weeks as the first stage of treatment. in combination with androgen deprivation therapy with agonists or antagonists of GnRH before performing radical radiation therapy (combined or remote). All patients underwent neoadjuvant hormone therapy: 16 patients – with the use of GnRH antagonists (Degarelix), 17 – with the use of GnRH agonists (Gozerelin/Leuprorelin/Triptorelin). The toxicity of the presented treatment regimen and its immediate effectiveness – the effect on the level of prostate‑s pecific antigen (PSA), prostate volume, and the quality of urination – were evaluated.Results. Treatment regimen was highly effective concerning PSA decrease (from initial median level 79,67 ng/ml to 1,45 ng/ml after neoadjuvant treatment), all subjects responded well, no non‑responders observed. Median prostate volume decreased from 44 cm3 to 25 cm3 after treatment, which guaranteed availability and safety of further radical radiation treatment. Urinary function was restored in all subject with initial urinary retention.Conclusion. Neoadjuvant chemo‑h ormonal treatment was highly effective in PSA level, prostate volume decrease and functional results improvement which secured further radical radiation treatment in one of its types. Toxicity was acceptable, adverse events did not exceed grade II in most cases and did not lead to treatment discontinuation in any cases, while quality of life remained high enough.
- Open Access
- 13 May 2023
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 19 (1) , 25-34-34
Retroperitoneoscopic access in organ-preserving treatment of renal cell carcinoma
Background. Renal cell carcinoma is one of the most common urologic cancers. Due to development of modern diagnostic methods, kidney tumors are often diagnosed at early stages (cT1a-T1b). The golden standard of treatment of localized renal cell carcinoma is tumor resection. In retroperitoneoscopic access, the time to artery access is decreased, the risk of intra- and postoperative complications is reduced. Retroperitoneal access is preferable for tumors located on the lateral or posterior kidney surface.Aim. To analyze the results of treatment of patients after retroperitoneoscopic kidney resection.Materials and methods. Between 2018 and 2021, at the A.F. Tsyb Medical Radiological Research Center - branch of the National Medical Research Radiological Center 47 retroperitoneoscopic kidney resections were performed (29 (61.7 %) in men, 18 (38.3 %) in women) due to stage cT1aN0M0 renal cell carcinoma. Retrospective analysis of demographic data, comorbid status, tumor characteristics, operative time, blood loss volume, frequency and severity of complications per the Clavien-Dindo classification was performed. Complexity of resection was evaluated using the R.E.N.A.L. scale.Results. Mean patient age was 63 (38-79) years, body mass index was 29.9 (22-39) kg/m2. Tumor of the left kidney was diagnosed in 24 (51.0 %) cases, of the right kidney - in 22 (46.8 %) cases, bilateral lesions - in 1 (2.2 %) case. Mean tumor size was 22.4 (11-39) mm. Resection had low complexity in 35 (74.5 %) cases, intermediate complexity in 12 (25.5 %) cases. Mean operative time was 156 (80-280) minutes, mean warm ischemia time was 19 (7-32) minutes, number of resections with zero ischemia was 15 (31.9 %), mean blood loss volume was 53 (10-300) mL, number of resections without renal parenchyma suturing was 10 (21.3 %). Mean hospitalization time after surgery was 5 days. Postoperative complications were observed in 4 (8.5 %) cases: bleeding (severity grade II per the Clavien-Dindo classification) in 1 (2.1 %) case, postoperative infectious complications (severity grade II) - in 2 (4.2 %) cases, subcutaneous hematoma (severity grade I) - in 1 (2.1 %) case.Conclusion. Retroperitoneoscopic access is effective and safe. This is confirmed by low frequency and severity of postoperative complications. This access allows to reduce hospitalization time and pain management medication which accelerates patient mobilization and recovery. Comparative analysis shows that retroperitoneoscopic kidney resection has the same effectiveness as laparoscopic resection.
- 13 May 2023
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 19 (1) , 25-34-34
Open AccessRetroperitoneoscopic access in organ-preserving treatment of renal cell carcinoma
Background. Renal cell carcinoma is one of the most common urologic cancers. Due to development of modern diagnostic methods, kidney tumors are often diagnosed at early stages (cT1a-T1b). The golden standard of treatment of localized renal cell carcinoma is tumor resection. In retroperitoneoscopic access, the time to artery access is decreased, the risk of intra- and postoperative complications is reduced. Retroperitoneal access is preferable for tumors located on the lateral or posterior kidney surface.Aim. To analyze the results of treatment of patients after retroperitoneoscopic kidney resection.Materials and methods. Between 2018 and 2021, at the A.F. Tsyb Medical Radiological Research Center - branch of the National Medical Research Radiological Center 47 retroperitoneoscopic kidney resections were performed (29 (61.7 %) in men, 18 (38.3 %) in women) due to stage cT1aN0M0 renal cell carcinoma. Retrospective analysis of demographic data, comorbid status, tumor characteristics, operative time, blood loss volume, frequency and severity of complications per the Clavien-Dindo classification was performed. Complexity of resection was evaluated using the R.E.N.A.L. scale.Results. Mean patient age was 63 (38-79) years, body mass index was 29.9 (22-39) kg/m2. Tumor of the left kidney was diagnosed in 24 (51.0 %) cases, of the right kidney - in 22 (46.8 %) cases, bilateral lesions - in 1 (2.2 %) case. Mean tumor size was 22.4 (11-39) mm. Resection had low complexity in 35 (74.5 %) cases, intermediate complexity in 12 (25.5 %) cases. Mean operative time was 156 (80-280) minutes, mean warm ischemia time was 19 (7-32) minutes, number of resections with zero ischemia was 15 (31.9 %), mean blood loss volume was 53 (10-300) mL, number of resections without renal parenchyma suturing was 10 (21.3 %). Mean hospitalization time after surgery was 5 days. Postoperative complications were observed in 4 (8.5 %) cases: bleeding (severity grade II per the Clavien-Dindo classification) in 1 (2.1 %) case, postoperative infectious complications (severity grade II) - in 2 (4.2 %) cases, subcutaneous hematoma (severity grade I) - in 1 (2.1 %) case.Conclusion. Retroperitoneoscopic access is effective and safe. This is confirmed by low frequency and severity of postoperative complications. This access allows to reduce hospitalization time and pain management medication which accelerates patient mobilization and recovery. Comparative analysis shows that retroperitoneoscopic kidney resection has the same effectiveness as laparoscopic resection.
- Open Access
- 26 March 2023
- Published by QUASAR, LLC in Research and Practical Medicine Journal
- Vol. 10 (1) , 111-125
Trimodal organ‑preserving treatment of muscle‑invasive bladder cancer
Purpose of the study. Generalization of the world experience of organ‑preserving treatment in muscle‑invasive bladder cancerMaterials and methods. The literature was searched in Medline, Cochrane Library, Elibrary and PubMed systems. Publications describing the modern possibilities of organ‑preserving treatment of muscle‑invasive bladder cancer were included, 58 of which were used to write this review.Results. The review highlights the results of international randomized and significant non‑randomized studies of organ‑preserving treatment in muscle‑invasive bladder cancer. Special attention is paid to the description of a modern combination of treatment methods to achieve its maximum effectiveness while maintaining the quality of life of patients. The analysis of the world literature was carried out, confirming the prospects of organ‑preserving treatment with careful selection of patients.Conclusion. Organ-preserving trimodal therapy for muscle‑invasive bladder cancer remains an alternative treatment strategy. Careful selection of patients plays a key role. The modern approach to trimodal therapy (TMT) is as follows: complete transurethral resection of the bladder (TURB), neoadjuvant or adjuvant chemotherapy, subsequent assessment of the response to treatment (re‑staging with TURB) should be performed; with a complete pathomorphological response, a course of remote radiation therapy up to TFD 60–66 Gy in the case of traditional fractionation (focal radiation therapy and the use of hypofractionation modes are also possible), using modern irradiation technologies (IGRT, IMRT). In case of an incomplete response, the implementation of the radical cystectomy (RCE) is shown. If a relapse occurs during follow‑up after treatment in the volume of TMT, a life‑saving RCE is shown.If the above conditions are met, the oncological results of treatment with TMT are equivalent to those during RCE, but require further study.
- 26 March 2023
- Published by QUASAR, LLC in Research and Practical Medicine Journal
- Vol. 10 (1) , 111-125
Open AccessTrimodal organ‑preserving treatment of muscle‑invasive bladder cancer
Purpose of the study. Generalization of the world experience of organ‑preserving treatment in muscle‑invasive bladder cancerMaterials and methods. The literature was searched in Medline, Cochrane Library, Elibrary and PubMed systems. Publications describing the modern possibilities of organ‑preserving treatment of muscle‑invasive bladder cancer were included, 58 of which were used to write this review.Results. The review highlights the results of international randomized and significant non‑randomized studies of organ‑preserving treatment in muscle‑invasive bladder cancer. Special attention is paid to the description of a modern combination of treatment methods to achieve its maximum effectiveness while maintaining the quality of life of patients. The analysis of the world literature was carried out, confirming the prospects of organ‑preserving treatment with careful selection of patients.Conclusion. Organ-preserving trimodal therapy for muscle‑invasive bladder cancer remains an alternative treatment strategy. Careful selection of patients plays a key role. The modern approach to trimodal therapy (TMT) is as follows: complete transurethral resection of the bladder (TURB), neoadjuvant or adjuvant chemotherapy, subsequent assessment of the response to treatment (re‑staging with TURB) should be performed; with a complete pathomorphological response, a course of remote radiation therapy up to TFD 60–66 Gy in the case of traditional fractionation (focal radiation therapy and the use of hypofractionation modes are also possible), using modern irradiation technologies (IGRT, IMRT). In case of an incomplete response, the implementation of the radical cystectomy (RCE) is shown. If a relapse occurs during follow‑up after treatment in the volume of TMT, a life‑saving RCE is shown.If the above conditions are met, the oncological results of treatment with TMT are equivalent to those during RCE, but require further study.
- Open Access
- 6 May 2022
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 18 (1) , 143-150-150
Rare malignant kidney (renal) tumor – leiomyosarcoma of the renal vein (clinical case)
Soft tissue sarcomas are a rare group of malignant tumors that develop from different types of connective tissue. One of the histological variants of primary renal sarcoma is renal leiomyosarcoma. Leiomyosarcoma of kidneys can develop from the renal vasculature, renal veins, pelvic muscles, smooth muscle components of the renal capsule. Clinical and radiologic signs of leiomyosarcoma are nonspecific. Diagnosis is based on histological and immunohistochemical studies after surgical intervention. This article presents a clinical case of diagnosis and treatment of leiomyosarcoma of the renal vein.
- 6 May 2022
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 18 (1) , 143-150-150
Open AccessRare malignant kidney (renal) tumor – leiomyosarcoma of the renal vein (clinical case)
Soft tissue sarcomas are a rare group of malignant tumors that develop from different types of connective tissue. One of the histological variants of primary renal sarcoma is renal leiomyosarcoma. Leiomyosarcoma of kidneys can develop from the renal vasculature, renal veins, pelvic muscles, smooth muscle components of the renal capsule. Clinical and radiologic signs of leiomyosarcoma are nonspecific. Diagnosis is based on histological and immunohistochemical studies after surgical intervention. This article presents a clinical case of diagnosis and treatment of leiomyosarcoma of the renal vein.
- Open Access
- 26 September 2021
- Published by QUASAR, LLC in Research and Practical Medicine Journal
- Vol. 8 (3) , 97-107
The role of biomarkers of acute kidney injury in predicting functional outcomes of surgical treatment of patients with localized kidney cancer
Currently, due to the dynamic development of surgical technologies, indications for organ-sparing treatment of kidney cancer are expanding. Acute kidney injury is a serious complication that leads to chronic kidney disease, increased postoperative mortality, deterioration of long-term functional outcomes, and increased hospitalization. At present, it is known that even a slight damage to kidneys or their impairment, presented by a decreased urine output and change in blood biochemical parameters, entails serious clinical consequences and is associated with a poor prognosis. Damaging factors, when the kidney is exposed, initially induce molecular changes, which entail the production of certain biomarkers, and only after that clinical aspects of kidney damage develop. The causes of acute kidney injury can be different, from specific renal disorders (acute interstitial nephritis, vascular and glomerular lesions, prerenal azotemia, obstructive disorders) to toxic damages, direct trauma and surgical treatment. The development of acute renal injury in the postoperative period is a serious complication of the surgical treatment of kidney disease, and, according to various authors, the frequency of its occurrence varies from 5.5 % to 34 %. An active study of this problem made it possible to find specific biomarkers that give the possibility to predict and diagnose acute renal injury in the early stages, to optimize the treatment strategy, to reduce the incidence of postoperative complications, and to shorten the period of postoperative rehabilitation. Currently, the most studied of acute kidney injury (AKI) biomarkers are cystatin C, neutrophil gelatinase-associated lipocalin‑2 (NGAL), hepatic protein L-FABP, KIM‑1 (Kidney injury molecule‑1), Interleukin – 18. Further study of AKI biomarkers will make it possible to determine the most significant ones for subsequent use in everyday practice
- 26 September 2021
- Published by QUASAR, LLC in Research and Practical Medicine Journal
- Vol. 8 (3) , 97-107
Open AccessThe role of biomarkers of acute kidney injury in predicting functional outcomes of surgical treatment of patients with localized kidney cancer
Currently, due to the dynamic development of surgical technologies, indications for organ-sparing treatment of kidney cancer are expanding. Acute kidney injury is a serious complication that leads to chronic kidney disease, increased postoperative mortality, deterioration of long-term functional outcomes, and increased hospitalization. At present, it is known that even a slight damage to kidneys or their impairment, presented by a decreased urine output and change in blood biochemical parameters, entails serious clinical consequences and is associated with a poor prognosis. Damaging factors, when the kidney is exposed, initially induce molecular changes, which entail the production of certain biomarkers, and only after that clinical aspects of kidney damage develop. The causes of acute kidney injury can be different, from specific renal disorders (acute interstitial nephritis, vascular and glomerular lesions, prerenal azotemia, obstructive disorders) to toxic damages, direct trauma and surgical treatment. The development of acute renal injury in the postoperative period is a serious complication of the surgical treatment of kidney disease, and, according to various authors, the frequency of its occurrence varies from 5.5 % to 34 %. An active study of this problem made it possible to find specific biomarkers that give the possibility to predict and diagnose acute renal injury in the early stages, to optimize the treatment strategy, to reduce the incidence of postoperative complications, and to shorten the period of postoperative rehabilitation. Currently, the most studied of acute kidney injury (AKI) biomarkers are cystatin C, neutrophil gelatinase-associated lipocalin‑2 (NGAL), hepatic protein L-FABP, KIM‑1 (Kidney injury molecule‑1), Interleukin – 18. Further study of AKI biomarkers will make it possible to determine the most significant ones for subsequent use in everyday practice